在病毒学抑制的HIV感染患者中，将替诺福韦/恩曲他滨/依非韦伦（TDF/FTC/EFV）转换为TDF/FTC/rilpivirine与继续使用TDF/FTC/EFV的比较：一项随机对照试验。
Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial.
作者信息
Wiriyatanakorn Sirichai, Sungkanuparph Somnuek
机构信息
Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.
出版信息
Open Forum Infect Dis. 2019 Jun 26;6(7):ofz297. doi: 10.1093/ofid/ofz297. eCollection 2019 Jul.
A randomized controlled noninferiority trial was conducted in HIV-infected patients receiving tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) with virological suppression in a resource-limited setting. Switching to TDF/FTC/rilpivirine was noninferior to continuing TDF/FTC/EFV in terms of maintaining compete viral suppression at 24 weeks and provided better lipid profiles and fewer central nervous system adverse effects.
在资源有限的环境中，对接受替诺福韦/恩曲他滨/依非韦伦（TDF/FTC/EFV）且病毒学得到抑制的HIV感染患者进行了一项随机对照非劣效性试验。在24周时维持完全病毒抑制方面，换用TDF/FTC/利匹韦林不劣于继续使用TDF/FTC/EFV，并且脂质状况更好，中枢神经系统不良反应更少。
Zotero 插件